Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma

Published:2013-07 Issue:7 Volume:15 Page:504-510
ISSN:1365-182X
Container-title:HPB
language:en
Short-container-title:HPB

Author:

Mathur Abhishek,Franco Edson S.,Leone John P.,Osman‐Mohamed Hussein,Rojas Haydy,Kemmer Nyingi,Neff Guy W.,Rosemurgy Alexander S.,Alsina Angel E.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Estimating the world cancer burden: GLOBOCAN 2000;Parkin;Int J Cancer,2001

2. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005;Altekruse;J Clin Oncol,2009

3. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End‐stage Liver Disease (MELD) organ allocation policy;Yao;Liver Transpl,2004

4. Prevalence and trends in obesity among US adults, 1999–2000;Flegal;JAMA,2002

5. Obesity: preventing and managing the global epidemic. Report of a WHO consultation;World Health Organ Tech Rep Ser,2000

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study;World Journal of Transplantation;2024-09-18

2. Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma;Cancers;2024-08-06

3. Long-term outcomes following hepatectomy in patients with lean non-alcoholic fatty liver disease-associated hepatocellular carcinoma versus overweight and obese counterparts: A multicenter analysis;Asian Journal of Surgery;2024-07

4. Body Mass Index: An Unreliable Adiposity Indicator for Predicting Outcomes of Liver Transplantation Due to Hepatocellular Carcinoma;Gastrointestinal Disorders;2024-06-25

5. Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab;Liver International;2024-03-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3